Abstract
The majority of patients with Wegener's granulomatosis (WG) or microscopic polyangiitis (MPA) have antineu-trophil cytoplasmic antibodies (ANCA) in their serum. This is particularly true of patients with “disseminated” disease, the great majority of whom are ANCA positive. WG and MPA are often termed “ANCA-associated vasculitides” (AAV), even though not all patients with these conditions have ANCA. The Churg—Strauss syndrome, another disorder classified as an AAV, is discussed in Chap. 23. Multiple antibodies may lead to positive immunofluores-cence testing for ANCA in either perinuclear (P-ANCA) or cytoplasmic (C-ANCA) patterns. However, only antibodies to myeloperoxidase (MPO) and proteinase-3 (PR3) are associated with the A AV. Antibodies directed against PR3 and MPO are termed PR3-ANCA and MPO-ANCA, respectively. WG may be associated with destructive upper respiratory tract disease, including saddle-nose deformity, erosive sinusitis, and subglottic stenosis. A host of ocular lesions may occur in the A AV, including episcleritis, scleritis, peripheral ulcerative keratitis, and orbital pseudotumor. Most of these lesions are more common in WG than in MPA. Lung disease in the AAV ranges from nodular lesions with a tendency to cavitate (in WG), to interstitial lung disease (MPA), and to alveolar hemorrhage (both WG and MPA). Segmental, necrotizing glomerulonephritis commonly accompanies the AAV. Because of the paucity of immunoreactants such as immunoglobulins and complement components in kidney biopsies relative to the biopsies from patients with immune complex-mediated glomerulonephritis, the glomerulonephritis of the A AV is termed “pauci-immune.”
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Antineutrophil cytoplasmic autoantibody-associated pauci-immune glomerulonephritis and vasculitis, and other vasculitides. In: D'Agati VD, Jennette JC, Silva FG (eds) Non-neoplastic kidney diseases (1st edn). Silver Spring, MD, ARP, 2005, pp. 385–424
Bajema IM, Bruijn JA. What stuff is this! A historical perspective on fibrinoid necrosis. J Pathol 2000; 191:235–238
Bean SM, Conner MG. Wegener's granulomatosis of the uterine cervix: A case report and review of the literature. Int J Gynecol Pathol 2007; 26:95–98
Bienaime F, Clerbaux G, et al D-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease. Am J Kidney Dis 2007; 50(5):821–825
Birnbaum J, Danoff S, Askin FB, Stone JH. Microscopic polyangiitis presenting as a ‘pulmonary-muscle’ syndrome: Does alveolar hemorrhage contribute to the mechanism of pulmonary fibrosis?. Arthritis Rheum 2007; 56(6):20–71
Boomsma MM, Stegeman CA, van der Leij MJ, et al Prediction of relapses in Wegener's granulomatosis by measurement of antineu-trophil cytoplasmic antibody levels. A prospective study. Arthritis Rheum 2000; 43:2025–2033
Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006; 368:404–418
Brons RH, de Jong MC, de Boer NK, et al Detection of immune deposits in skin lesions of patients with Wegener's granulomatosis. Ann Rheum Dis 2001; 60:1097–1102
Carrington CB, Liebow A. Limited forms of angiitis and granulomato-sis of Wegener's type. Am J Med 1966; 41:497–527
D'Cruz DP, Baguley E, Asherson RA, et al Ear, nose, and throat symptoms in subacute Wegener's granulomatosis. BMJ 1989; 299: 419–422
Devaney KO, Travis WD, Hoffman G, et al Interpretation of head and neck biopsies in Wegener's granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 1990; 14:555–564
Duggan CP, Westra SJ, Rosenberg AE. Case records of the Massachusetts General Hospital. Case 23–2007. A 9-year-old boy with bone pain, rash, and gingival hypertrophy. N Engl J Med 2007; 357:392–400
Eisenberger U, Fakhouri F, Vanhille P, et al ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrol Dial Transplant 2005; 20:1392–1399
Eschun GM, Mink SN, Sharma S. Pulmonary interstitial fibrosis as a presenting manifestation in perinuclear antineutrophilic cytoplas-mic antibody microscopic polyangiitis. Chest 2003; 123:297–301
FDA Public Health Notification: Complications from metallic tracheal stents in patients with benign airway disorders. http://www.fda.gov/cdrh/safety/072905-tracheal.html
Feriozzi S, Muda AO, et al Cephotaxime-associated allergic interstitial nephritis and MPO-ANCA positive vasculitis. Ren Fail 2000; 22(2):245–251
Finkielman JD, Lee AS, Hummel AM, et al ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med 2007; 120:643.e9–e14
Finkielman JD, Merkel PA, Schroeder D, et al for the WGET Research Group. Antineutrophil cytoplasmic antibodies against proteinase 3 do not predict disease relapses in Wegener's granulomatosis. Ann Intern Med 2007 147(9):611–9
Franssen C, Gans R, Kallenberg C, et al Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: Distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies. J Intern Med 1998 244:209–216
Gallagher H, Kwan JT, Jayne DR. Pulmonary renal syndrome: A 4-year, single-center experience. Am J Kidney Dis 2002; 39:42–47
Geetha D, Seo P. Renal transplantation in the ANCA-associated vascu-litides. Am J Transplant 2007; 7:2657–2662
Geffriaud-Ricouard C, Noël LH, Chauveau D. Clinical significance of ANCA in 98 patients. Adv Exp Med Biol 1993; 336:273–279
Genereau T, Lortholary O, Pottier M, et al Temporal artery biopsy. A diagnostic tool for systemic necrotizing vasculitis. Arthritis Rheum 1999; 42:2674–2681
Gera M, Griffin MD, Specks U, et al Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression. Kidney Int 2007; 71:1296–1301
Goek ON, Stone JH. Randomized controlled trials in ANCA-associated vasculitis. Curr Opin Rheumatol 2005; 17:257–264
Guillevin L, Durand-Gasselin B, Cevallos R. Microscopic polyangiitis: Clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42:421–430
Gunton JE, Stiel J, et al Prevalence of positive anti-neutrophil cytoplas-mic antibody (ANCA) in patients receiving anti-thyroid medication. Eur J Endocrinol 2000; 142(6):587
Haas M, Eustace JA. Immune complex deposits in ANCA-associated crescentic glomerulonephritis: A study of 126 cases. Kidney Int 2004; 65:2145–2152
Harris AA, Falk RJ, Jennette JC. Crescentic glomerulonephritis with a paucity of glomerular immunoglobulin localization. Am J Kidney Dis 1998; 32:179–184
Haubitz M et al Cyclophosphamide phramacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 2002; 61: 1495–1501
Hauer HA, Bajema IM, de Heer E, et al Distribution of renal lesions in idiopathic systemic vasculitis: A three-dimensional analysis of 87 glomeruli. Am J Kidney Dis 2000; 36:257–265
Hauer HA, Bajema IM, van Houwelingen HC, et al Renal histology in ANCA-associated vasculitis: Differences between diagnostic and serologic subgroups. Kidney Int 2002; 61:80–89
Hoffman G, Kerr G, Leavitt R, et al Wegener's granulomatosis: An analysis of 158 patients. Ann Intern Med 1992; 116:488–498
Holvast A, Stegeman CA, Benne CA, et al Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination. Ann Rheum Dis 2008 July 14. [Epub ahead of print]
Hollander D, Manning RT. The use of alkylating agents in the treatment of Wegener's granulomatosis. Ann Intern Med 1967; 67:393–8
Homma S, Matsushita H, Nakata K. Pulmonary fibrosis in myeloper-oxidase antineutrophil cytoplasmic antibody-associated vasculiti-des. Respirology 2004; 9(2):190–196
Javaud N, Belenfant X, Stirnemann J, et al Renal granulomatoses: A retrospective study of 40 cases and review of the literature. Medicine (Baltimore) 2007; 86:170–180
Jayne D, Rasmussen N, Bacon, et al Randomised trial of cyclo-phosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis. N Engl J Med 2003; 349: 36–44
Jayne DR, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. QJM 1995; 88:127–133
Jayne DR, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. QJM 1995; 88:127–133
Kyndt et al Serial measurements of antineutrophil cytoplasmic autoan-tibodies in patients with systemic vasculitis. Am J Med 1999; 106:527–533
Langford C, Talar-Williams C, Barron K, et al A staged approach to the treatment of Wegener's granulomatosis: Induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42: 2666–2673
Leavitt RY, Fauci AS, Bloch DA, et al The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33:1101–1107
Luqmani RA, Bacon PA, Beaman, et al Classical versus non-renal Wegener's granulomatosis. Q J Med 1994; 87:161–167
Mahr AD, Neogi T, LaValley MP, et al Assessment of the item selection and weighting in the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) (submitted)
Merkel PA, Lo GH, Holbrook JT, et al for the WGET Research Group. Incidence of venous thrombotic events among patients with Wegener's granulomatosis. Ann Intern Med 2005; 142:620–626
Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7(1):33–9
Nachman PH, Segelmark M, Westman K, et al Recurrent ANCA-associated small vessel vasculitis after transplantation: A pooled analysis. Kidney Int 1999; 56:1544–1550
Nasr SH, D'Agati VD, Park, et al Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. Clin J Am Soc Nephrol 2008; 3:682–690
Niles JL, Böttinger EP, Saurina GR, et al The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. Arch Intern Med 1996; 156:440–445
Polychronopoulos VS, Prakash UB, Golbin JM, et al Airway involvement in Wegener's granulomatosis. Rheum Dis Clinics N America 2007; 33:755–775
Reinhold-Keller E, Beuge N, Latza U, et al An interdisciplinary approach to the care of patients with Wegener's granulomatosis. Long term outcome in 155 patients. Arthritis Rheum 2000; 43(5):1021–1032
Robinson MR, Lee SS, Sneller MC, et al Tarsal-conjunctival disease associated with Wegener's granulomatosis. Ophthalmology 2003; 110:1770–1780
Rostaing L, Modesto A, Oksman F et al Outcome of patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis following cadaveric kidney transplantation. Am J Kidney Dis 1997; 29(1):96–102
Sadiq Z, Shepherd R, Vardy S. Posterior scleritis: An unusual presentation of facial pain. Br J Oral Maxillofac Surg 2003; 41:62–63
Sakai N, Wada T, et al Tubulointerstitial nephritis with anti-neutrophil cytoplasmic antibody following indomethacin treatment. Nephrol Dial Transplant 1999; 14(11):2774
Saxena R, Bygren P, Arvastson B, Wieslander J. Circulating autoanti-bodies as serological markers in the differential diagnosis of pulmonary renal syndrome. J Intern Med 1995; 238:43–52
Slot MC, Links TP, et al Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: A long-term followup study. Arthritis Rheum 2005; 53(1):108–113
Small P, Brisson M-L. Wegener's granulomatosis presenting as temporal arteritis. Arthritis Rheum 1991; 34:220–223
Sneller MC, Hoffmann GS, Talar-Williams C, et al An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38:608–613
Specks U et al Design of the rituximab in ANCA-associated vasculitis (RAVE) trial. 2009 (in press)
Stassen PM, Sanders JS, Kallenberg CG, Stegeman CA. Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2008; 23:654–658
Stassen PM, Derks RPH, Kallenberg CGM, Stegeman CA. Thiopurinemethyltransferase (TPMT) genotype and TPMT activity in patients with anti-neutrophil cytoplasmic antibody-associated vas-culitis: relation to azathioprine maintenance treatment and adverse effects. Ann Rheum Dis Ann Rheum Dis 2009; 68(5):758–9
Stegeman CA, Cohen Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CGM. Association of nasal carriage of Staphylococcus aureus and higher relapse in Wegener's Granulomatosis. Ann Intern Med 1994; 120:12–17
Stegeman CA. Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculi-tis. Nephrol Dial Transplant 2002; 17(12):2077–80
Stone J, Millward C, Criswell L. Two Unusual Genitourinary Manifestations Of Wegener's Granulomatosis. The Journal of Rheumatology 1997; 24(11): 1846–1848
Stone JH: and the Wegener's Granulomatosis Etanercept Trial Research Group. Limited versus severe Wegener's granulomatosis: Baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 2003; 48:2299–2309
Stone JH, Hoffman GS, Wegener's Granulomatosis. In: Hochberg MC, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology (4th edn). London, Elsevier, 2006, pp. 72.1–72.25
Suryaprasad A, Stone JH. When is it safe to stop Pneumocystis carinii (jiroveci) prophylaxis? Insights from cases complicating autoimmune diseases. Arthritis Care & Research 2008; 59(7):1034–9
The WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials 2002; 23: 450–468
The WGET Research Group. Etanercept plus standard therapy in patients with wegener's granulomatosis. N Engl J Med 2005; 352:351–361
Wainright J, Davson J. The renal appearances in the microscopic form of periarteritis nodosa. J Pathol Bacteriol 1950; 62:189–196
Wegener F. Uber generalisierte, septische Gefasserkrankungen. Verh Dtsch Ges Pathol 1936; 29:202
Wegener F. Über eine eigenartige rhinogene Granulomatose mit beson-derer Beteiligung des Arteriensystems und der Nieren. Beitr Pathol 1939; 102:36
Wiesner O, Russell KA, Lee AS, et al Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum 2004; 50:2954–2965
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Stone, J.H. et al. (2009). ANCA-Associated Vasculitis. In: Stone, J.H. (eds) A Clinician's Pearls and Myths in Rheumatology. Springer, London. https://doi.org/10.1007/978-1-84800-934-9_24
Download citation
DOI: https://doi.org/10.1007/978-1-84800-934-9_24
Publisher Name: Springer, London
Print ISBN: 978-1-84800-933-2
Online ISBN: 978-1-84800-934-9
eBook Packages: MedicineMedicine (R0)